Announcements Trials
Browse Landscape

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 56Lung Neoplasms 48Leukemia, Myeloid, Acute 44Breast Neoplasms 37Carcinoma, Non-Small-Cell Lung 36Myelodysplastic Syndromes 27Pancreatic Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Multiple Myeloma 23Colorectal Neoplasms 23Carcinoma, Renal Cell 22Neoplasm Metastasis 20Melanoma 20Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Brain Neoplasms 16Triple Negative Breast Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Hepatocellular 12Lymphoma, Mantle-Cell 11Lymphoma, B-Cell 11Leukemia, Myelomonocytic, Chronic 11Fallopian Tube Neoplasms 11Rectal Neoplasms 10Myeloproliferative Disorders 10Lymphoma, Follicular 10Colonic Neoplasms 10Hematopoietic and Lymphatic System Neoplasm 9

Interventions

Specimen Handling 2talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Breast Adenocarcinoma × Specimen Handling × Clear all
NCT04517838 2025-12-24

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Mayo Clinic

Recruiting
230 enrolled
Breast

Breast Adenocarcinoma

NCT05447910 2025-06-15

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Mayo Clinic

Terminated
21 enrolled
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡